Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs.
Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs.
复制标题
核糖体中的抗性：RUNX1、前 LSC 和 HSPC。
DOI：
10.1016/j.stem.2015.07.012
复制
发表时间：
2015
期刊：
影响因子：
23.9
通讯作者：
Ito,Keisuke
中科院分区：
文献类型：
--
作者：
Ito,Kyoko;Ito,Keisuke
白血病前干细胞（pre-LSC）的治疗靶向可能是根除残留疾病和预防白血病复发的可行策略。现在在Cell Stem Cell，Cai et al.（2015）表明，RUNX 1中的功能缺失突变减少了核糖体生物合成，并通过增加应激抗性为前LSC提供了优于正常造血细胞的选择性优势。
Therapeutic targeting of pre-leukemic stem cells (pre-LSCs) may be a viable strategy to eradicate residual disease and prevent leukemia relapse. Now inCell Stem Cell, Cai et al. (2015) show that loss-of-function mutations inRUNX1reduce ribosome biogenesis and provide pre-LSCs a selective advantage over normal hematopoietic cells through increased stress resistance.